KR20230169651A - Cosmetic composition with oxygen nano bubble water and peptide complex - Google Patents
Cosmetic composition with oxygen nano bubble water and peptide complex Download PDFInfo
- Publication number
- KR20230169651A KR20230169651A KR1020220070057A KR20220070057A KR20230169651A KR 20230169651 A KR20230169651 A KR 20230169651A KR 1020220070057 A KR1020220070057 A KR 1020220070057A KR 20220070057 A KR20220070057 A KR 20220070057A KR 20230169651 A KR20230169651 A KR 20230169651A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- cosmetic composition
- peptide complex
- oxygen
- present
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 45
- 239000001301 oxygen Substances 0.000 title claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 239000002101 nanobubble Substances 0.000 title claims abstract description 36
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 25
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 24
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 12
- 235000004883 caffeic acid Nutrition 0.000 claims description 12
- 229940074360 caffeic acid Drugs 0.000 claims description 12
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 12
- 239000002105 nanoparticle Substances 0.000 claims description 5
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 claims description 4
- 230000003020 moisturizing effect Effects 0.000 abstract description 18
- 231100000274 skin absorption Toxicity 0.000 abstract description 14
- 230000037384 skin absorption Effects 0.000 abstract description 14
- 210000003491 skin Anatomy 0.000 description 52
- 239000000126 substance Substances 0.000 description 18
- 239000004615 ingredient Substances 0.000 description 10
- 239000013543 active substance Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000035807 sensation Effects 0.000 description 7
- 231100000245 skin permeability Toxicity 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000037317 transdermal delivery Effects 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 4
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 4
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- -1 pack Substances 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036548 skin texture Effects 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 230000006750 UV protection Effects 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 229940069445 licorice extract Drugs 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 150000002894 organic compounds Chemical group 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OWPUOLBODXJOKH-UHFFFAOYSA-N 2,3-dihydroxypropyl prop-2-enoate Chemical compound OCC(O)COC(=O)C=C OWPUOLBODXJOKH-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- CUZKCNWZBXLAJX-UHFFFAOYSA-N 2-phenylmethoxyethanol Chemical compound OCCOCC1=CC=CC=C1 CUZKCNWZBXLAJX-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 241001310324 Cetraria islandica Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000181025 Rosa gallica Species 0.000 description 1
- 235000011402 Rosa x damascena Nutrition 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- QRSFFHRCBYCWBS-UHFFFAOYSA-N [O].[O] Chemical compound [O].[O] QRSFFHRCBYCWBS-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical group CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 108010051489 calin Proteins 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Chemical group 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001749 primary amide group Chemical group 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000003156 secondary amide group Chemical group 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000000917 skin toxin Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 125000003142 tertiary amide group Chemical group 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 산소나노버블수 및 펩타이드 복합체를 포함하는 화장료 조성물에 관한 것이다. 본 발명에서 제공하는 화장료 조성물은 피부에 효과적으로 전달하여 피부 흡수율을 증가시킬 수 있으며, 수분감 및 보습감이 우수한 화장료 조성물을 제공할 수 있다.The present invention relates to a cosmetic composition containing oxygen nanobubble water and a peptide complex. The cosmetic composition provided by the present invention can be effectively delivered to the skin, increase skin absorption rate, and provide a cosmetic composition with excellent moisture and moisturizing properties.
Description
본 발명은 산소나노버블수 및 펩타이드 복합체를 포함하는 화장료 조성물에 관한 것으로, 구체적으로 산소나노버블수 및 펩타이드 복합체를 포함하여 피부 흡수율을 증진시켜 수분감 및 보습감이 우수한 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing oxygen nanobubble water and a peptide complex, and specifically relates to a cosmetic composition containing oxygen nanobubble water and a peptide complex to improve skin absorption and provide excellent moisture and moisturizing sensation.
피부의 구조상 각질층의 수분이 감소하면 피부가 건조해지고 표면이 거칠게 되며 피부가 윤기를 잃어 칙칙하게 보이는 현상 등의 피부 노화를 나타내게 되어 건강하고 탄력 있는 피부 표현을 위해서는 피부 보습이 중요하다. 피부의 보습 관리를 위해 시중에서는 수분을 흡수하는 성질, 수분 증발을 방지하는 성질 또는 수분 보유를 증가시키는 방식을 이용하는 등의 다양한 보습제가 출시되고 있다.Due to the structure of the skin, when the moisture in the stratum corneum decreases, the skin becomes dry, the surface becomes rough, the skin loses its luster, appears dull, and other signs of skin aging occur. Moisturizing the skin is important to express healthy and elastic skin. In order to manage skin's moisture, various moisturizers are being released on the market that use moisture-absorbing properties, properties that prevent moisture evaporation, or methods that increase moisture retention.
피부는 표피, 진피, 피하지방 등으로 구성되어 있다. 특히 표피는 상피조직(epithelial tissue)으로 구성되어 있는 피부의 가장 바깥쪽 층으로서 모두 다섯 개의 층으로 구성되어 있다. 구체적으로 바닥쪽에서부터 기저층(basal layer), 가시층(spinous layer), 과립층(granular layer), 투명층(clear layer) 및 각질층(horny layer)으로 이루어져 있으며 최외각에 존재하는 각질층은 외부 환경 유래의 다양한 화합물 및 자극을 차단하여 일차 방어막의 역할을 수행한다. 따라서, 이러한 각질층의 장벽 기능으로 인하여 피부 효능 물질 또는 생리 활성 물질의 경피 전달이 충분히 이루어지지 못하는 문제가 있다.The skin is composed of the epidermis, dermis, and subcutaneous fat. In particular, the epidermis is the outermost layer of the skin composed of epithelial tissue and consists of a total of five layers. Specifically, from the bottom, it is composed of a basal layer, spinous layer, granular layer, clear layer, and horny layer, and the stratum corneum present in the outermost layer is a variety of substances derived from the external environment. It acts as a primary defense shield by blocking compounds and stimuli. Therefore, there is a problem that transdermal delivery of skin-effective substances or physiologically active substances cannot be sufficiently achieved due to the barrier function of the stratum corneum.
최근 들어, 종래 이러한 문제를 해결하기 위하여 각질층의 구조를 변경시켜 각질층의 장벽 기능을 약화시키는 투과촉진제를 사용되고 있는데, 투과 촉진제의 경우 피부 세포에 대한 독성이 높고 피부의 자극을 유발할 가능성이 매우 높은 문제점을 가진다. 이에 따라 초음파, LED, 미세 전류 등 물리적 자극원을 이용하여 전달 효율을 높이는 시도를 하고 있지만, 전달 효과 등에서는 예측하지 못하고 있다. 이에 따라, 피부 효능 물질 또는 생리 활성 물질의 경피 전달을 효과적으로 달성할 수 있는 방법의 개발이 필요한 실정이다.Recently, in order to solve this problem, permeation accelerators have been used to weaken the barrier function of the stratum corneum by changing the structure of the stratum corneum. However, permeation accelerators are highly toxic to skin cells and have a very high possibility of causing skin irritation. has Accordingly, attempts are being made to increase delivery efficiency by using physical stimulation sources such as ultrasound, LED, and microcurrent, but the delivery effect is not predictable. Accordingly, there is a need to develop a method that can effectively achieve transdermal delivery of skin-effective substances or bioactive substances.
이에 따라, 본 발명자는 산소나노버블수 및 펩타이드 복합소재를 포함하여 피부흡수율을 증진시켜 효과적인 생리활성물질의 경피 전달이 가능한 화장료 조성물을 개발하여 본 발명에 이르게 되었다.Accordingly, the present inventor developed a cosmetic composition containing oxygen nanobubble water and a peptide composite material that improves skin absorption rate and enables effective transdermal delivery of bioactive substances, leading to the present invention.
본 발명은 산소나노버블수 및 펩타이드 복합체를 포함하여 피부흡수율을 증진시켜 우수한 수분감 및 보습감의 효과가 있는 화장료 조성물을 제공하고자 한다.The present invention seeks to provide a cosmetic composition containing oxygen nanobubble water and a peptide complex that improves skin absorption and provides excellent moisture and moisturizing effects.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업계에서 통상의 지식을 가진 자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description below.
본 발명의 일 실시예에 따르면, 산소나노버블수 및 펩타이드 복합체를 포함하는 화장료 조성물이 제공된다.According to one embodiment of the present invention, a cosmetic composition containing oxygen nanobubble water and a peptide complex is provided.
본 발명에서 상기 산소나노버블수는 30ppm이상의 산소가 포함되어 있는 것을 특징으로 하는 화장료 조성물일 수 있다.In the present invention, the oxygen nanobubble water may be a cosmetic composition characterized in that it contains more than 30 ppm of oxygen.
본 발명에서 상기 산소나노버블수의 나노입자는 150nm이하인 화장료 조성물일 수 있다.In the present invention, the nanoparticles of the oxygen nanobubble water may be a cosmetic composition of 150 nm or less.
본 발명에서 상기 펩타이드 복합체는 아세틸헥사펩타이드를 포함하는 것을 특징으로 하는 화장료 조성물일 수 있다.In the present invention, the peptide complex may be a cosmetic composition characterized by comprising acetyl hexapeptide.
본 발명에서 상기 펩타이드 복합체는 상기 화장료 조성물 총 중량에 대하여, 0.001 내지 0.5중량%로 포함되는 화장료 조성물일 수 있다.In the present invention, the peptide complex may be included in a cosmetic composition in an amount of 0.001 to 0.5% by weight based on the total weight of the cosmetic composition.
본 발명에서 상기 화장료 조성물은 카페익산을 더 포함하는 화장료 조성물일 수 있다.In the present invention, the cosmetic composition may be a cosmetic composition further containing caffeic acid.
본 발명에서 제공하는 화장료 조성물은 산소나노버블수 및 펩타이드 복합소재를 포함하여 피부흡수율을 증진시켜 우수한 수분감 및 보습감의 효과가 있을 뿐만 아니라, 피부 효능 물질 또는 생리 활성 물질의 경피 전달을 효과적으로 할 수 있다.The cosmetic composition provided by the present invention contains oxygen nanobubble water and peptide composite materials to improve skin absorption rate, thereby providing excellent moisture and moisturizing effects, as well as effective transdermal delivery of skin-effective substances or bioactive substances. .
이하, 보다 구체적으로 설명하기 위해 실시예를 들어 상세하게 설명하기로 한다. 그러나, 하기 실시예는 예시적인 것으로, 본 발명의 범위가 이에 제한되는 것은 아니다.Hereinafter, in order to explain in more detail, examples will be given in detail. However, the following examples are illustrative and the scope of the present invention is not limited thereto.
본 발명의 일 실시예에 따르면, 산소나노버블수 및 펩타이드 복합체를 포함하는 화장료 조성물에 관한 것이다.According to one embodiment of the present invention, it relates to a cosmetic composition containing oxygen nanobubble water and a peptide complex.
본 발명에서 상기 화장료 조성물은 피부 효능 물질 또는 생리 활성 물질을 더 포함할 수 있고, 상기 피부 효능 물질 또는 생리 활성 물질은 통상적으로 사용되는 피부 효능 물질 또는 생리 활성 물질일 수 있다.In the present invention, the cosmetic composition may further include a skin-effective substance or a physiologically active substance, and the skin-effective substance or a physiologically active substance may be a commonly used skin-effective substance or a physiologically active substance.
예를 들어, 상기 피부 효능 물질 또는 상기 생리 활성 물질은 미백, 피부탄력, 주름개선, 수분, 보습, 항노화, 항아토피, 자외선 차단을 위한 것일 수 있고, 비타민A, 비타민 C, 비타민 E, 아스타잔틴, 코엔자임 큐10, 알부틴, 살리실산, 코직산, 알파-리포산, 엘라직산, 레스베라, 유용성 감초 추출물, 도코사헥사엔산, 에이코사펜타엔산, 리놀레산, 글루타치온 및 카페익산에서 선택되는 어느 하나 이상일 수 있으나, 이에 제한되지 않는다.For example, the skin efficacious substance or the physiologically active substance may be for whitening, skin elasticity, wrinkle improvement, moisture, moisturizing, anti-aging, anti-atopy, and UV protection, and may include vitamin A, vitamin C, vitamin E, and asbestos. Any one selected from tarzanthin, coenzyme Q10, arbutin, salicylic acid, kojic acid, alpha-lipoic acid, ellagic acid, resvera, oil-soluble licorice extract, docosahexaenoic acid, eicosapentaenoic acid, linoleic acid, glutathione, and caffeic acid. It may be more than this, but is not limited thereto.
본 발명에서 용어 "산소나노버블수"는 산소나노버블을 포함하는 물을 의미한다. 상기 "산소나노버블"은 물을 나노 크기로 기포화한 후, 기포 속에 산소를 주입하여 제조한 것을 의미한다.In the present invention, the term “oxygen nanobubble water” refers to water containing oxygen nanobubbles. The “oxygen nanobubble” refers to a product manufactured by bubbles of water into nano-sized bubbles and then injecting oxygen into the bubbles.
본 발명에서 상기 산소나노버블수에 함유된 산소(Oxygen)는 사람을 포함한 호기성 생물의 생존에 필수불가결한 물질이다. 사람은 코와 입뿐만 아니라 피부로도 산소를 공급하며 피부호흡은 전체 호흡량의 0.6% 정도를 차지한다. 피부 호흡은 피부 열 발산, 유독물질(피부독소) 배설, 수분증발 등의 기능과 피부의 신진대사 기능을 수행한다.In the present invention, oxygen (Oxygen) contained in the oxygen nanobubble water is an essential substance for the survival of aerobic organisms, including humans. Humans supply oxygen not only through the nose and mouth, but also through the skin, and skin respiration accounts for about 0.6% of total respiration. Skin respiration performs functions such as skin heat dissipation, toxic substances (skin toxins) excretion, moisture evaporation, and skin metabolism.
피부의 산소결핍이 발생할 경우, 피부 호흡 또는 신진대사 과정 저해를 유발할 수 있고 이에 따라 피부 세포 내 수분보충이 충분하게 되지 않아 피부 세포의 턴오버를 저해시켜 멜라닌이 원활히 배출되지 않고 축적되어 기미나 주근깨, 점 등과 같은 과색소침착증을 유발할 수 있다.When oxygen deficiency occurs in the skin, it can cause inhibition of skin respiration or metabolic processes, and as a result, insufficient moisture replenishment within skin cells inhibits skin cell turnover, causing melanin to accumulate and not be discharged smoothly, causing blemishes or freckles. , may cause hyperpigmentation such as moles.
본 발명에 따른 산소나노버블수를 함유한 화장료 조성물을 사용할 경우, 피부 세포 내 수분보충을 증진시켜 피부의 신진대사 과정을 향상시킬 수 있고 이에 따라 피부탄력 및 미백효과를 가질 수 있다. 또한 상기 화장료 조성물의 피부흡수율을 향상시켜 피부 효능 물질 또는 생리 활성 물질의 경피 전달을 효과적으로 할 수 있다.When using a cosmetic composition containing oxygen nanobubble water according to the present invention, the metabolic process of the skin can be improved by enhancing moisture replenishment within skin cells, and thus skin elasticity and whitening effects can be achieved. In addition, the skin absorption rate of the cosmetic composition can be improved, thereby enabling effective transdermal delivery of skin-effective substances or physiologically active substances.
본 발명의 상기 산소나노버블수에는 30ppm 이상의 산소가 포함될 수 있고, 화장료 조성물의 피부 흡수율을 높여, 피부 장벽을 개선하여, 피부 보습 효과 등의 기능성을 향상시키는 측면에서 적합하게는 30ppm 내지 120ppm의 산소가 포함되는 것을 특징으로 하는 화장료 조성물일 수 있다.The oxygen nanobubble water of the present invention may contain 30 ppm or more of oxygen, and is preferably 30 ppm to 120 ppm of oxygen in terms of increasing the skin absorption rate of the cosmetic composition, improving the skin barrier, and improving functionality such as skin moisturizing effect. It may be a cosmetic composition characterized in that it contains.
예를 들어, 상기 산소나노버블수의 산소 농도가 30ppm미만일 경우, 피부의 흡수율을 향상시키는 효과가 발생하지 않을 수 있고, 120ppm을 초과하는 경우 다량의 산소로 피부에 자극이 발생하는 문제점이 나타날 수 있다.For example, if the oxygen concentration of the oxygen nanobubble water is less than 30ppm, the effect of improving skin absorption rate may not occur, and if it exceeds 120ppm, the problem of skin irritation due to a large amount of oxygen may occur. there is.
본 발명의 상기 산소나노버블수의 나노입자 평균 크기는 30nm 내지 150nm의 크기일 수 있고, 상기 화장료 조성물의 피부 흡수율을 증진시키는 측면에서 적합하게는 50nm 내지 100nm 인 것을 특징으로 하는 화장료 조성물일 수 있다.The average size of the nanoparticles of the oxygen nanobubble water of the present invention may be 30 nm to 150 nm, and is preferably 50 nm to 100 nm in terms of improving the skin absorption rate of the cosmetic composition. .
예를 들어, 상기 산소나노버블수의 나노입자가 30nm미만일 경우, 입자의 크기가 현저하게 작아 상기 화장료 조성물 내에서 산소나노버블을 유지하기 어렵거나, 상기 펩타이드 복합체 또는 기타의 성분들과 결합을 형성하기 어려운 문제점이 발생할 수 있고, 150nm를 초과할 경우 상기 화장료 조성물이 피부에 효과적으로 흡수되지 않는 문제점이 발생할 수 있다.For example, when the nanoparticles of the oxygen nanobubble water are less than 30 nm, the size of the particles is significantly small, making it difficult to maintain the oxygen nanobubbles in the cosmetic composition, or forming bonds with the peptide complex or other components. Problems that make it difficult to do so may occur, and if it exceeds 150 nm, a problem may occur in which the cosmetic composition is not effectively absorbed into the skin.
본 발명에서 상기 화장료 조성물 총 중량에 대하여 상기 산소나노버블수는 60 내지 98 중량%, 65 내지 97 중량% 또는 70 내지 96 중량% 포함될 수 있고, 상기 화장료 조성물의 피부 흡수를 증진시키는 측면에서 적합하게는 75 내지 95 중량% 포함되는 화장료 조성물일 수 있으나, 이에 제한되지 않는다.In the present invention, the oxygen nanobubble water may be included in an amount of 60 to 98% by weight, 65 to 97% by weight, or 70 to 96% by weight based on the total weight of the cosmetic composition, and is suitably used in terms of enhancing skin absorption of the cosmetic composition. The cosmetic composition may contain 75 to 95% by weight, but is not limited thereto.
본 발명에서 상기 펩타이드는 아미드 결합(또는 펩타이드 결합)으로 연결된 하나 이상의 아미노산으로 구성된 폴리머를 의미할 수 있고, 당업계에 공지된 화학적 합성 방법, 특히 고상 합성 기술(solid-phase synthesis techniques)에 따라 제조될 수 있다.In the present invention, the peptide may refer to a polymer composed of one or more amino acids linked by amide bonds (or peptide bonds), and is manufactured according to chemical synthesis methods known in the art, especially solid-phase synthesis techniques. It can be.
상기 펩타이드 복합체는 생체 안전성, 피부 활성, 피부 주름, 피부 탄력, 피부결, 피부 수분감 및 보습감의 개선 효과를 나타내는 펩타이드 복합체를 의미할 수 있다. The peptide complex may refer to a peptide complex that exhibits improvement effects on biosafety, skin activity, skin wrinkles, skin elasticity, skin texture, skin moisture, and moisturizing sensation.
본 발명의 상기 펩타이드 복합체는 헥사펩타이드를 포함할 수 있고, 안정적으로 피부 효능 물질 또는 생리 활성 물질을 진피층까지 전달하기 위한 측면에서 적합하게는 아세틸헥사펩타이드를 포함하는 것을 특징으로 하는 화장료 조성물일 수 있다.The peptide complex of the present invention may contain a hexapeptide, and may be a cosmetic composition characterized by containing acetylhexapeptide, suitably in terms of stably delivering skin effective substances or physiologically active substances to the dermal layer. .
예를 들어, 상기 헥사펩타이드는 Glu-Glu-Met-Gln-Arg-Arg의 아미노산 서열을 갖는 헥사펩타이드를 의미하고, 헥사펩타이드는 헥사펩타이드의 C-말단에 카르복시기가 아마이드기로 치환된 것일 수 있고, 상기 아마이드기는 1차, 2차 및 3차 아마이드기로 이루어지는 군으로부터 선택되는 어느 하나의 아마이드기 일 수 있으나, 이에 제한되지 않는다.For example, the hexapeptide refers to a hexapeptide having the amino acid sequence of Glu-Glu-Met-Gln-Arg-Arg, and the hexapeptide may be one in which the carboxyl group at the C-terminus of the hexapeptide is replaced with an amide group, The amide group may be any one amide group selected from the group consisting of primary, secondary and tertiary amide groups, but is not limited thereto.
예를 들어, 상기 아세틸헥사펩타이드는 아세트산(acetic acid) 및 헥사펩타이드-8의 반응물인 아세틸헥사펩타이드-8(Acetyl Hexapeptide-8)를 포함할 수 있고, 구체적으로 아세틸헥사펩타이드-8은 하기 화학식 1의 구조(Ac- Glu-Glu-Met-Gln-Arg-Arg -NH2)를 포함할 수 있다.For example, the acetyl hexapeptide may include acetyl hexapeptide-8, which is a reaction product of acetic acid and hexapeptide-8. Specifically, acetyl hexapeptide-8 has the formula 1 below: It may include the structure (Ac- Glu-Glu-Met-Gln-Arg-Arg -NH2).
[화학식 1][Formula 1]
. .
상기 아세틸헥사펩타이드-8은 뇌가 보낸 신경 전달 물질 신호 또는 아세틸콜린의 분비를 방해하여, 기존 주름을 감소시키고 새로이 형성되는 주름을 자연스럽고 안전하게 억제하는 효과가 있어 주름방지에 효과적일 뿐만 아니라 콜라겐 및 엘라스틴 손상을 억제해 피부탄력과 피부결의 개선에 효과적일 수 있다. 또한 수용성 성분으로 수분함유량이 높은 제형과 함께 사용할 경우 피부 흡수율이 증진되어 우수한 수분감 및 보습감의 효과를 가질 수 있다.The acetylhexapeptide-8 interferes with the secretion of acetylcholine or neurotransmitter signals sent by the brain, thereby reducing existing wrinkles and suppressing newly formed wrinkles naturally and safely. It is not only effective in preventing wrinkles, but also promotes collagen and It can be effective in improving skin elasticity and texture by suppressing elastin damage. In addition, when used with a formulation with a high moisture content as a water-soluble ingredient, skin absorption rate is improved, resulting in excellent moisture and moisturizing effects.
본 발명의 상기 펩타이드 복합체는 상기 화장료 조성물 총 중량에 대하여, 0.001 내지 0.5중량%, 0.005 내지 0.3중량% 또는 0.007 내지 0,1 중량% 포함될 수 있고, 안정적으로 상기 화장료 조성물을 피부에 효과적으로 전달하기 위한 측면에서 적합하게는 0.01 내지 0.05중량%로 포함되는 화장료 조성물일 수 있다.The peptide complex of the present invention may be included in an amount of 0.001 to 0.5% by weight, 0.005 to 0.3% by weight, or 0.007 to 0.1% by weight, based on the total weight of the cosmetic composition, and is used to effectively and stably deliver the cosmetic composition to the skin. In terms of suitability, it may be a cosmetic composition containing 0.01 to 0.05% by weight.
예를 들어, 상기 펩타이드 복합체를 상기 화장료 조성물 총 중량에 대하여 0.001중량% 미만으로 포함할 경우, 상기 화장료 조성물의 피부흡수율이 현저하게 낮아져 수분감 및 보습감의 효과가 저해될 수 있거나 피부 효능 물질 또는 생리 활성 물질의 피부 전달이 효과적으로 이루어 지지 않는 문제점이 발생할 수 있rh, 0.5중량%를 초과하여 포함할 경우, 피부에 자극이 나타나는 문제점이 발생할 수 있다.For example, when the peptide complex is included in an amount of less than 0.001% by weight based on the total weight of the cosmetic composition, the skin absorption rate of the cosmetic composition may be significantly lowered, which may impede the effect of moisture and moisturizing sensation, or may inhibit skin-effective substances or physiological activities. Problems may arise in which the substance is not effectively delivered to the skin, and if it contains more than 0.5% by weight, skin irritation may occur.
본 발명의 상기 화장료 조성물은 카페익산을 더 포함하는 화장료 조성물일 수 있다.The cosmetic composition of the present invention may be a cosmetic composition further containing caffeic acid.
본 발명에서 상기 카페익산(Caffeic acid)은 모든 식물에서 발견되고 있는데, 히드록시신남산(hydroxycinnamic acid)으로 분류되는 유기화합물로서 페놀기와 아크릴기로 이루어지며, 상기 유기 화합물은 바이오매스의 주요 원천인 리그닌(lignin) 생합성의 중요 중간체일 수 있다. 또한 상기 카페익산은 인 비트로 및 인 비보에서 강력한 항산화 활성을 가질 수 있고, 면역조절 및 항염증 활성의 효과를 가질 수 있으며, 피지 감소, 여드름 예방 및 개선 효과를 가질 수 있다.In the present invention, caffeic acid is found in all plants. It is an organic compound classified as hydroxycinnamic acid and consists of a phenol group and an acrylic group. The organic compound is lignin, the main source of biomass. (lignin) may be an important intermediate in biosynthesis. In addition, the caffeic acid may have strong antioxidant activity in vitro and in vivo, may have immunomodulatory and anti-inflammatory effects, and may have sebum reduction, acne prevention and improvement effects.
예를 들어, 상기 카페익산은 상기 화장료 조성물 총 중량에 대하여, 0.001 내지 0.5중량%, 0.005 내지 0.3중량% 또는 0.01 내지 0.2 중량% 포함될 수 있고, 피부 효능 물질 또는 항산화 또는 피지개선을 위한 측면에서 적합하게는 0.01 내지 0.1중량%로 포함될 수 있다.For example, the caffeic acid may be included in an amount of 0.001 to 0.5% by weight, 0.005 to 0.3% by weight, or 0.01 to 0.2% by weight, based on the total weight of the cosmetic composition, and is suitable as a skin efficacious substance or antioxidant or sebum improvement. It may be included in an amount of 0.01 to 0.1% by weight.
본 발명에서 상기 화장료 조성물은 세라마이드 복합체를 더 포함할 수 있다.In the present invention, the cosmetic composition may further include a ceramide complex.
본 발명에서 상기 화장료 조성물은 피부 수분 또는 보습을 위한 것일 수 있고, 미백, 피부결 개선, 탄력증진, 주름개선, 자외선 차단, 항산화 또는 피지 개선용일 수 있다.In the present invention, the cosmetic composition may be for skin moisture or moisturizing, whitening, skin texture improvement, elasticity improvement, wrinkle improvement, UV protection, antioxidant or sebum improvement.
본 명세서에서 용어 "화장료 조성물"은 인체를 청결, 미화하여 매력을 더하고 용모를 밝게 변화시키거나 피부, 모발의 건강을 유지 또는 증진하기 위하여 인체에 사용되는 물품을 의미한다.As used herein, the term "cosmetic composition" refers to an article used on the human body to clean and beautify the human body, add attractiveness, brighten the appearance, or maintain or promote the health of skin and hair.
상기 화장료 조성물은 본 발명의 목적을 해하지 않는 내에서 점증제, 방부제, 안정화제, 용해화제, 계면활성제, 담체, 및 향로로 이루어진 그룹에서 선택되는 어느 하나 이상을 포함하는 화장료 조성물일 수 있고, 또한 통상의 화장료에 배합되는 다른 성분 및 기능성 성분을 추가적으로 배합할 수도 있다.The cosmetic composition may be a cosmetic composition containing at least one selected from the group consisting of a thickener, preservative, stabilizer, solubilizer, surfactant, carrier, and incense agent, as long as it does not impair the purpose of the present invention, and Other ingredients and functional ingredients that are blended in ordinary cosmetics can also be additionally blended.
상기 화장료 조성물의 종류는 특별히 제한되지 않으나, 적합하게는 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐로션, 영양로션, 맛사지크림, 영양크림, 모이스쳐크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클렌저로 이루어진 그룹에서 선택될 수 있고, 피부 외용제, 의약외품, 항균 또는 수분공급용 약학적 조성물로 이루어진 그룹에서 선택되는 어느 하나일 수 있다.The type of the cosmetic composition is not particularly limited, but suitable examples include skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutritional lotion, massage cream, nutritional cream, moisture cream, hand cream, foundation, It can be selected from the group consisting of essence, nutritional essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, and body cleanser, and can be selected from the group consisting of external skin preparations, quasi-drugs, and pharmaceutical compositions for antibacterial or moisturizing purposes. It can be any one of them.
상기 피부 외용제는 크림, 겔, 연고, 피부 유화제, 피부 현탁액, 경피전달성 패치, 약물 함유 붕대, 로션, 또는 그 조합일 수 있다. 상기 피부 외용제는 통상 화장품이나 의약품 등의 피부외용제에 사용되는 성분, 예를 들면 수성성분, 유성성분, 분말성분, 알코올류, 보습제, 증점제, 자외선흡수제, 미백제, 방부제, 산화방지제, 계면활성제, 향료, 색제, 각종 피부 영양제, 또는 이들의 조합과 필요에 따라서 적절하게 배합될 수 있다.The external skin agent may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal delivery patch, drug-containing bandage, lotion, or a combination thereof. The skin external preparations include ingredients commonly used in external skin preparations such as cosmetics and medicines, such as aqueous ingredients, oil-based ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, and fragrances. , colorants, various skin nutrients, or a combination thereof may be appropriately mixed according to need.
상기 피부외용제는, 에데트산이나트륨, 에데트산삼나트륨, 시트르산나트륨, 폴리인산나트륨, 메타인산나트륨, 글루콘산 등의 금속봉쇄제, 카페인, 탄닌, 벨라파밀, 감초추출물, 글라블리딘, 칼린의 과실의 열수추출물, 각종생약, 아세트산토코페롤, 글리틸리틴산, 트라넥삼산 및 그 유도체 또는 그 염등의 약제, 비타민 C, 아스코르브산인산마그네슘, 아스코르브산글루코시드, 알부틴, 코지산, 글루코스, 프룩토스, 트레할로스 등의 당류 등도 적절하게 배합할 수 있다.The skin external preparations include metal sequestrants such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid, caffeine, tannin, belafamil, licorice extract, glablidin, and calin. Hot water extract of fruit, various herbal medicines, drugs such as tocopherol acetate, glytylitinic acid, tranexamic acid and its derivatives or salts, vitamin C, magnesium ascorbate phosphate, ascorbate glucoside, arbutin, kojic acid, glucose, fructose, Sugars such as trehalose can also be appropriately mixed.
이하, 본 발명을 하기의 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be explained in detail by the following examples. However, the following examples only illustrate the present invention, and the content of the present invention is not limited by the following examples.
실시예Example
제조예. 산소나노버블수의 제조Manufacturing example. Production of oxygen nanobubble water
산소나노버블 발생장치에서 정제수를 사용하여 평균크기 100 nm 이하의 산소나노버블수를 제조하였다. 상기 나노버블 발생장치는 기포캡슐레이션 방법 등을 이용하는 통상적인 장치를 사용하였다.Oxygen nanobubble water with an average size of 100 nm or less was produced using purified water in an oxygen nanobubble generator. The nanobubble generator used was a conventional device using a bubble encapsulation method.
실험예. 산소나노버블수 및 펩타이드 복합체에 따른 효능평가Experiment example. Efficacy evaluation based on oxygen nanobubble water and peptide complex
(산소 30ppm 이상)Oxygen Nanobubble Water
(Oxygen 30ppm or more)
상기 표 1에서 보는 바와 같이, 실시예 및 비교예의 각 구성성분을 다르게 포함하며 화장료 조성물을 제조하였다. 구체적으로, 산소나노버블수는 제조예에 따라 제조되었고, 펩타이드 복합체는 아세틸헥사펩타이드-8를 사용하였다. As shown in Table 1, cosmetic compositions were prepared containing different components of Examples and Comparative Examples. Specifically, oxygen nanobubble water was prepared according to the preparation example, and acetylhexapeptide-8 was used as the peptide complex.
또한, 추가 성분 20종은 프로필렌글라이콜다이카프릴레이트/다이카프레이트를 1.15중량% 포함하고 글리세린, 다이프필렌글라이콜 및 1,2-헥산다이올을 각각 1.05중량% 포함하고, 포트마리골드꽃추출물, 아이슬란드이끼추출물, 다마스크장미꽃추출물, 글리세릴아크릴레이트/아크릴릭애씨드코폴리머, 암모늄아크릴로일다이메틸타우레이트/브이피코폴리머, 아크릴레이트/C10-30알킬아크릴레이트크로스폴리머, 세테아릴글루코사이드, 솔비탄올리베이트, 세테아릴알코올, 향료, 트로메타민, 부틸렌글라이콜, 소듐하이알루로네이트크로스폴리머, 벤질글라이콜, 에틸헥실글리세린 및 글리세릴글루코사이드를 각각 0.1 중량% 포함하였다. In addition, 20 additional ingredients include propylene glycol dicaprylate/dicaprate at 1.15% by weight, glycerin, dippylene glycol, and 1,2-hexanediol at 1.05% by weight each, and pot Marigold flower extract, Iceland moss extract, damask rose flower extract, glyceryl acrylate/acrylic acid copolymer, ammonium acryloyl dimethyl taurate/V picopolymer, acrylate/C10-30 alkyl acrylate crosspolymer, 0.1% by weight each of cetearyl glucoside, sorbitan olivate, cetearyl alcohol, fragrance, tromethamine, butylene glycol, sodium hyaluronate crosspolymer, benzyl glycol, ethylhexyl glycerin, and glyceryl glucoside. included.
다음으로, 상기 표 1에 따라 제조된 화장료 조성물의 피부투과도 평가 및 관능평가를 측정하여 하기 표 2 및 3에 나타내었다.Next, the skin permeability evaluation and sensory evaluation of the cosmetic composition prepared according to Table 1 were measured and shown in Tables 2 and 3 below.
1.피부투과도 평가1. Skin permeability evaluation
피부투과도는 Franz cell 시험법을 이용하여 측정하였다. 구체적으로, 피부대용품(실험에 사용된 멤브레인: Merck millipore 사 Start-M membrane)의 한쪽 면에 상기 표 1에 따른 화장료 조성물을 도포하고, 다른 한쪽면에는 체액의 성분으로 구성된 용액(용출액, Media)을 접촉시킴으로써 카페익산의 투과도(피부)를 측정하였다. 용액의 온도는 피부 내 온도와 같은 37를 유지하며, 시간대별로 용출액 모두를 채취한 후 농축하여 HPLC를 통하여 투과된 카페익산의 함량을 분석하여 하기 표 2에 나타내었다.Skin permeability was measured using the Franz cell test. Specifically, the cosmetic composition according to Table 1 above was applied to one side of a skin substitute (membrane used in the experiment: Start-M membrane manufactured by Merck Millipore), and a solution (eluate, media) composed of components of body fluid was applied to the other side. The permeability (skin) of caffeic acid was measured by contacting with . The temperature of the solution is 37 degrees Celsius, which is the same as the temperature inside the skin. was maintained, all of the eluates were collected for each time period, concentrated, and the content of permeated caffeic acid was analyzed through HPLC, which is shown in Table 2 below.
상기 표 2에서 보는 바와 같이, 산소나노버블수를 포함한 실시예 1의 경우, 정제수를 포함한 비교예1과 대비하여 시간대별 카페익산의 피부 투과성이 1.7배 내지 2.5배 높은 것을 확인할 수 있었다.As shown in Table 2, in the case of Example 1 containing oxygen nanobubble water, it was confirmed that the skin permeability of caffeic acid over time was 1.7 to 2.5 times higher than that of Comparative Example 1 containing purified water.
따라서, 산소나노버블수를 포함할 경우 카페익산의 투과성 증가에 영향을 주는 것을 알 수 있었다.Therefore, it was found that the inclusion of oxygen nanobubble water had an effect on increasing the permeability of caffeic acid.
2. 관능평가2. Sensory evaluation
관능평가는 남녀 20(연령분포 19~35세)명을 대상으로 수행하였으며 상기 표 1에 따라 제조된 화장료 조성물들을 피부에 도포하여 초기수분감, 보습감 및 전반적인 사용감에 대하여 조사하였다. 구체적으로, 초기수분감은 도포시 제형의 촉촉한 정도, 보습감은 도포후 느껴지는 보습감을 중심으로 조사하였으며, 매우좋음: 5점, 좋음 : 4점, 보통 : 3점, 나쁨 : 2점, 매우나쁨 : 1점의 평가기준으로 평가하였다.Sensory evaluation was conducted on 20 men and women (age distribution 19-35 years old), and the cosmetic compositions prepared according to Table 1 above were applied to the skin and examined for initial moisture, moisturizing sensation, and overall feeling of use. Specifically, the initial moisture sensation was investigated based on the moistness of the formulation upon application, and the moisturizing sensation was investigated based on the moisturizing sensation felt after application. Very good: 5 points, good: 4 points, average: 3 points, bad: 2 points, very bad: 1. It was evaluated based on the evaluation criteria of points.
상기 표 3에서 보는 바와 같이, 산소나노버블수를 포함한 실시예 1 경우 초기수분감, 보습감 및 전반적인 사용감 모두 4.0점 이상으로 우수하며 관능평가결과의 평균값이 4.1점 이상으로 현저하게 우수한 것을 확인할 수 있었다.As shown in Table 3 above, in the case of Example 1 including oxygen nanobubble water, the initial moisture feeling, moisturizing feeling, and overall feeling of use were all excellent at 4.0 points or higher, and the average value of the sensory evaluation results was confirmed to be significantly superior at 4.1 points or higher.
다음으로, 비교예 1은 정제수를 포함하는 경우로, 3.3점의 평균값으로 실시예 1과 대비하여 현저하게 낮은 사용감을 가지는 것을 확인할 수 있었다.Next, Comparative Example 1 contained purified water, and it was confirmed that it had a significantly lower feeling of use compared to Example 1, with an average value of 3.3 points.
이에 따라, 본 발명과 같이 산소나노버블수 및 펩타이드 복합체를 포함하는 경우 피부투과성 또는 피부흡수율을 증진시켜 피부 효능 물질 또는 생리 활성 물질의 피부투과성을 증진시킬 수 있고, 산소를 피부에 공급함에 따라 피부의 신진대사를 활성화하여 우수한 수분감 및 보습감과 사용감증진의 효과를 가질 수 있다.Accordingly, when oxygen nanobubble water and peptide complex are included as in the present invention, skin permeability or skin absorption rate can be improved to improve skin permeability of skin effective substances or physiologically active substances, and by supplying oxygen to the skin, the skin permeability or skin absorption rate can be improved. By activating metabolism, it can provide excellent hydration, moisturizing effect, and improved feeling of use.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현 예일뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.As the specific parts of the present invention have been described in detail above, it is clear to those skilled in the art that these specific techniques are merely preferred implementation examples and do not limit the scope of the present invention. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (6)
상기 산소나노버블수는 30ppm이상의 산소가 포함되어 있는 것을 특징으로 하는 화장료 조성물.According to paragraph 1,
A cosmetic composition characterized in that the oxygen nanobubble water contains more than 30 ppm of oxygen.
상기 펩타이드 복합체는 아세틸헥사펩타이드를 포함하는 것을 특징으로 하는 화장료 조성물.According to paragraph 1,
A cosmetic composition characterized in that the peptide complex includes acetylhexapeptide.
상기 펩타이드 복합체는 상기 화장료 조성물 총 중량에 대하여, 0.001 내지 0.5중량%로 포함되는 화장료 조성물.According to paragraph 1,
A cosmetic composition in which the peptide complex is contained in an amount of 0.001 to 0.5% by weight based on the total weight of the cosmetic composition.
상기 화장료 조성물은 카페익산을 더 포함하는 화장료 조성물.According to paragraph 1,
The cosmetic composition further includes caffeic acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220070057A KR20230169651A (en) | 2022-06-09 | 2022-06-09 | Cosmetic composition with oxygen nano bubble water and peptide complex |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220070057A KR20230169651A (en) | 2022-06-09 | 2022-06-09 | Cosmetic composition with oxygen nano bubble water and peptide complex |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20230169651A true KR20230169651A (en) | 2023-12-18 |
Family
ID=89309502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220070057A KR20230169651A (en) | 2022-06-09 | 2022-06-09 | Cosmetic composition with oxygen nano bubble water and peptide complex |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20230169651A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210087397A (en) | 2020-01-02 | 2021-07-12 | 주식회사 에셀바이오팜 | Cosmetic composition containing hydrogen nano bubble |
-
2022
- 2022-06-09 KR KR1020220070057A patent/KR20230169651A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210087397A (en) | 2020-01-02 | 2021-07-12 | 주식회사 에셀바이오팜 | Cosmetic composition containing hydrogen nano bubble |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101282708B (en) | External preparation for skin containing a phosphorlated saccharide | |
EP3332762B1 (en) | Topical composition containing glycerin and yeast extract | |
WO2002047656A1 (en) | Compositions for retarding skin aging | |
US20100129465A1 (en) | Methods and Compositions Related to Acne Treatment | |
JP2010536764A (en) | Cosmetic method and cosmetic composition for repairing human skin | |
MXPA04006896A (en) | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis. | |
KR20110086894A (en) | Cosmetic included to alkaline powder & solution of shell | |
MX2012002424A (en) | Skin care formulations. | |
WO2005087182A1 (en) | Functional powders | |
JPWO2004016236A1 (en) | Cosmetics | |
KR102265730B1 (en) | cosmetic composition for skin wrinkle improvement and whitening facial skin | |
US9468597B1 (en) | Stabilized L-ascorbic acid skin serum | |
TWI352600B (en) | Cosmetic treatment system and methods | |
JP6731425B2 (en) | Obtaining extracts from brown alga gametophytes and their use as cosmetic anti-aging active ingredients | |
JP2005306831A (en) | Skin care preparation for external use | |
KR20220114509A (en) | Cleansing agent composition and cleanser prepared thereby | |
JP2000273033A (en) | Gel comprising natural material | |
KR20180118409A (en) | Nutrition Cream Containing Ergothioneine and Its Manufacturing Method | |
JP2004210653A (en) | Skin care preparation for external use | |
CN108697630B (en) | Methods and compositions for lightening skin using a chaetomium cupreum cell culture extract | |
WO2006101119A1 (en) | Collagen synthesis promoter | |
JP2013184942A (en) | Antioxidant and dna damage inhibitor | |
KR101736478B1 (en) | Method for manufacturing lotions with effective in treating acne | |
KR102267938B1 (en) | Moisturizing cosmetics that improve skin absorption, including asiatic pennywort extract, anemarrhena asphodeloides root extract, apricot seed oil, and peptides having antioxidant activity, and a method for manufacturing the same | |
KR20230169651A (en) | Cosmetic composition with oxygen nano bubble water and peptide complex |